Urispas en es it fr

Urispas Brand names, Urispas Analogs

Urispas Brand Names Mixture

  • No information avaliable

Urispas Chemical_Formula


Urispas RX_link

No information avaliable

Urispas fda sheet

Urispas msds (material safety sheet)

Urispas Synthesis Reference

No information avaliable

Urispas Molecular Weight

1140.24 g/mol

Urispas Melting Point

No information avaliable

Urispas H2O Solubility

Practically insoluble

Urispas State


Urispas LogP


Urispas Dosage Forms

Injection (50 mg vials to be reconstituted prior to injection)

Urispas Indication

For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.

Urispas Pharmacology

Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.

Urispas Absorption

No information avaliable

Urispas side effects and Toxicity

During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).

Urispas Patient Information

Urispas Organisms Affected

Aspergillis, Candida and other fungi